Status:

COMPLETED

IMRT vs 2DRT for NPC Patients

Lead Sponsor:

Chinese University of Hong Kong

Conditions:

NPC

Eligibility:

All Genders

Brief Summary

Irradiation of the parotid gland with subsequent long-term xerostomia is a well-recognized complication after radiotherapy for head and neck (HAN) cancers. A number of studies have shown that IMRT cou...

Eligibility Criteria

Inclusion

  • The NPC patient, who had been enrolled, randomized and treated in the prior prospective randomized study of IMRT vs 2DRT.
  • Regular follow-up for more than five years from the end of study intervention (i.e. IMRT or 2DRT for NPC).
  • Patient is able to sign the study-specific informed consent.
  • ECOG performance status 0 or 1.
  • Patient is able to complete the study's questionnaire.

Exclusion

  • NPC patients who had not been randomized or allocated to the study intervention, even though had been enrolled in the prior reported study.
  • Loss of regular follow-up from the end of study intervention.
  • Regular follow-up for less than five years from the end of study intervention.
  • Patients with known recurrent or metastatic disease.
  • Patients with secondary malignancy occurred after completion of the previous study's treatment (i.e. radiotherapy).
  • Active untreated infections
  • Major medical or psychiatric illness

Key Trial Info

Start Date :

November 29 2017

Trial Type :

OBSERVATIONAL

Allocation :

ACTUAL

End Date :

June 30 2021

Estimated Enrollment :

60 Patients enrolled

Trial Details

Trial ID

NCT03352778

Start Date

November 29 2017

End Date

June 30 2021

Last Update

October 22 2021

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

The Chinese University of Hong Kong

Hong Kong, Hong Kong